[go: up one dir, main page]

HK1202534A1 - 取代苯化合物 - Google Patents

取代苯化合物

Info

Publication number
HK1202534A1
HK1202534A1 HK15103015.8A HK15103015A HK1202534A1 HK 1202534 A1 HK1202534 A1 HK 1202534A1 HK 15103015 A HK15103015 A HK 15103015A HK 1202534 A1 HK1202534 A1 HK 1202534A1
Authority
HK
Hong Kong
Prior art keywords
substituted benzene
benzene compounds
compounds
substituted
benzene
Prior art date
Application number
HK15103015.8A
Other languages
English (en)
Inventor
凱文．韋恩．孔茨
理查德．切茲沃斯
肯尼思．威廉姆．鄧肯
海克．凱爾哈克
納塔利．沃霍里克
克莉絲汀．克勞斯
薩拉．
．克努森
關真志
提摩西．詹姆斯．尼爾森．維格勒
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of HK1202534A1 publication Critical patent/HK1202534A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15103015.8A 2011-04-13 2015-03-24 取代苯化合物 HK1202534A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474825P 2011-04-13 2011-04-13
US201161505676P 2011-07-08 2011-07-08
PCT/US2012/033662 WO2012142513A1 (en) 2011-04-13 2012-04-13 Substituted benzene compounds

Publications (1)

Publication Number Publication Date
HK1202534A1 true HK1202534A1 (zh) 2015-10-02

Family

ID=46000399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103015.8A HK1202534A1 (zh) 2011-04-13 2015-03-24 取代苯化合物

Country Status (20)

Country Link
US (2) US9376422B2 (zh)
EP (3) EP3470396A1 (zh)
JP (1) JP2014513084A (zh)
KR (1) KR101975613B1 (zh)
CN (1) CN104066718B (zh)
AR (1) AR086839A1 (zh)
AU (2) AU2012242604B2 (zh)
BR (1) BR112013026308B1 (zh)
CA (1) CA2832846C (zh)
DK (1) DK2697198T3 (zh)
ES (1) ES2590489T3 (zh)
HK (1) HK1202534A1 (zh)
HU (1) HUE030722T2 (zh)
IL (1) IL228746B (zh)
MX (1) MX344530B (zh)
PL (1) PL2697198T3 (zh)
PT (1) PT2697198T (zh)
RU (2) RU2017126990A (zh)
TW (2) TWI598336B (zh)
WO (1) WO2012142513A1 (zh)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841142C (en) 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) * 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
BR112014025506B1 (pt) 2012-04-13 2024-02-06 Epizyme, Inc Composição que compreende composto inibidor de ezh2, uso terapêutico da mesma e método in vitro de inibição da proliferação de células de câncer
PT3184523T (pt) 2012-04-13 2019-09-26 Eisai R&D Man Co Ltd Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2014049488A1 (en) * 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
HUE046790T2 (hu) 2012-10-15 2020-03-30 Epizyme Inc A rák kezelésének módszerei
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders
TWI494424B (zh) * 2012-11-20 2015-08-01 Dow Global Technologies Llc 可蒸餾燃料標記物
AU2013371541B2 (en) * 2012-12-13 2016-10-13 Glaxosmithkline Llc Enhancer of Zeste Homolog 2 inhibitors
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9346761B2 (en) 2013-03-14 2016-05-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153226A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
HUE046653T2 (hu) 2013-03-15 2020-03-30 G1 Therapeutics Inc Normál sejtek tranziens védelme kemoterápia során
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN105308038B (zh) * 2013-04-30 2018-05-29 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2的抑制剂
AU2014288839B2 (en) * 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
AU2014337300B2 (en) 2013-10-16 2019-01-03 Eisai R&D Management Co., Ltd. Hydrochloride salt form for EZH2 inhibition
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
JP2016539134A (ja) 2013-12-06 2016-12-15 エピザイム，インコーポレイティド 癌を治療するための併用療法
MX2021007651A (es) 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
UA118380C2 (uk) * 2014-06-17 2019-01-10 Пфайзер Інк. Заміщені сполуки дигідроізохінолінону
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
EP3206688A4 (en) 2014-10-16 2018-06-13 Epizyme, Inc. Method for treating cancer
BR112017008840A2 (pt) * 2014-10-28 2017-12-19 Glaxosmithkline Ip No 2 Ltd intensificador de inibidores do homólogo 2 de zeste
SI3220916T1 (sl) 2014-11-17 2023-09-29 Epizyme, Inc. Postopek zdravljenja raka z n-((4,6-dimetil-2-okso-1,2-dihidropiridin-3 -il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'- (morfolinometil)-(1,1'-bifenil)-3-karboksamidom
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2016101956A2 (en) 2014-12-23 2016-06-30 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
WO2016187394A1 (en) * 2015-05-19 2016-11-24 Van Wijnen Andre J Methods and materials for promoting bone formation
US20180311251A1 (en) 2015-06-10 2018-11-01 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
MX2018002344A (es) 2015-08-24 2018-07-06 Epizyme Inc Metodo para tratar el cancer.
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
LT3378859T (lt) * 2015-11-19 2020-01-27 Jiangsu Hengrui Medicine Co., Ltd. Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
RU2738844C2 (ru) * 2016-04-14 2020-12-17 Гуанчжоу Джойо Фарматек Ко., Лтд Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
CN108314677B (zh) * 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
CN110191879A (zh) * 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11672800B2 (en) * 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
AU2018269268B2 (en) 2017-05-18 2022-01-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
US11390614B2 (en) 2017-11-10 2022-07-19 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing benzofuran derivative
CN111356478A (zh) 2017-11-14 2020-06-30 辉瑞大药厂 Ezh2抑制剂组合疗法
US11485738B2 (en) 2018-01-31 2022-11-01 Mirati Therapeutics, Inc. Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
CA3106589A1 (en) 2018-07-27 2020-01-30 Suzhou Sinovent Pharma Co., Ltd. Polysubstituted benzene compound and preparation method and use thereof
EP3898597A1 (en) 2018-12-21 2021-10-27 Les Laboratoires Servier SAS Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
EP3950676A4 (en) * 2019-03-25 2022-08-10 Shanghai Synergy Pharmaceutical Sciences Co., Ltd METHOD FOR THE PREPARATION OF AMIDE COMPOUND AND ITS APPLICATION IN THE FIELD OF MEDICINE
JP7541538B2 (ja) 2019-06-05 2024-08-28 ミラティ セラピューティクス，インク． 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN113248481B (zh) * 2021-04-19 2023-03-24 中山大学 Ezh2共价不可逆抑制剂、制备方法及其用途
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
KR20250023483A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 퀴놀론 bcl6 이작용성 분해제

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
AU694465B2 (en) 1993-12-27 1998-07-23 Eisai Co. Ltd. Anthranilic acid derivative
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6060099A (en) 1998-09-30 2000-04-17 Procter & Gamble Company, The 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100828982B1 (ko) * 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US20050101590A1 (en) 2002-02-19 2005-05-12 Kiyoshi Yasui Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
TWI324926B (en) * 2004-04-23 2010-05-21 Bristol Myers Squibb Co Monocyclic heterocycles as kinase inhibitors
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
PL1940821T3 (pl) 2005-10-19 2013-08-30 Gruenenthal Gmbh Nowe ligandy receptora waniloidowego i ich zastosowanie do wytwarzania leków
RU2008119994A (ru) 2005-10-21 2009-12-10 Мерк энд Ко., Инк. (US) Ингибиторы калиевых каналов
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
JP2009519966A (ja) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
EP1974055A4 (en) 2006-01-20 2010-01-27 Univ North Carolina DIAGNOSTIC AND THERAPEUTIC OBJECTIVES AGAINST LEUKEMIA
AU2007333021A1 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors
WO2007136592A2 (en) * 2006-05-18 2007-11-29 Amphora Discovery Corporation 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
EP2086318A4 (en) 2006-10-10 2009-12-23 Burnham Inst Medical Research NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
US8247401B2 (en) 2007-10-31 2012-08-21 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
PL2229391T3 (pl) 2007-12-19 2015-02-27 Cancer Research Tech Ltd Pirydo[2,3-b]pirazyno-8-podstawione związki i ich zastosowanie
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
JP5548197B2 (ja) * 2008-08-08 2014-07-16 ニューヨーク ブラッド センター， インコーポレイテッド レトロウイルスの集合及び成熟の小分子阻害剤
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
AU2011248068B2 (en) 2010-05-07 2014-09-11 Glaxosmithkline Llc Indoles
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2607064T3 (es) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013003635A1 (en) 2011-06-28 2013-01-03 Stoplift, Inc. Image processing to prevent access to private information
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2888021A1 (en) 2012-10-15 2014-04-24 Epizyme, Inc. Substituted n-((2-oxo-1,2-dihydropyridin-3-yl)-methyl)-benzamide compounds and their use in the treatment of ezh2-mediated disorders

Also Published As

Publication number Publication date
RU2629118C2 (ru) 2017-08-24
KR101975613B1 (ko) 2019-05-07
CA2832846C (en) 2022-04-19
TW201305107A (zh) 2013-02-01
MX2013011922A (es) 2014-04-10
EP2697198A1 (en) 2014-02-19
US20160332969A1 (en) 2016-11-17
AU2012242604B2 (en) 2017-05-25
HUE030722T2 (en) 2017-05-29
MX344530B (es) 2016-12-19
CN104066718A (zh) 2014-09-24
EP3470396A1 (en) 2019-04-17
IL228746A0 (en) 2013-12-31
RU2017126990A (ru) 2019-02-01
AR086839A1 (es) 2014-01-29
CN104066718B (zh) 2017-08-29
AU2012242604A1 (en) 2013-10-24
JP2014513084A (ja) 2014-05-29
RU2017126990A3 (zh) 2020-10-30
US20140142083A1 (en) 2014-05-22
AU2017218920A1 (en) 2017-09-07
TW201733984A (zh) 2017-10-01
WO2012142513A1 (en) 2012-10-18
KR20140034787A (ko) 2014-03-20
RU2013150510A (ru) 2015-05-20
EP3165520B1 (en) 2018-08-15
US9376422B2 (en) 2016-06-28
DK2697198T3 (en) 2016-09-19
EP3165520A1 (en) 2017-05-10
PL2697198T3 (pl) 2016-12-30
BR112013026308A2 (pt) 2022-07-19
IL228746B (en) 2019-08-29
CA2832846A1 (en) 2012-10-18
TWI598336B (zh) 2017-09-11
EP2697198B1 (en) 2016-06-08
PT2697198T (pt) 2016-09-13
ES2590489T3 (es) 2016-11-22
BR112013026308B1 (pt) 2024-01-02

Similar Documents

Publication Publication Date Title
IL286152A (en) Modified imidazopyridinyl-aminopyridine compounds
IL265437A (en) Converted gasoline compounds
HK1202534A1 (zh) 取代苯化合物
PT2710018T (pt) Compostos macrocíclicos como inibidores de proteína quinases
GB201118652D0 (en) New compounds
GB201118654D0 (en) New compounds
GB201106799D0 (en) Novel compounds
HUE044576T2 (hu) Újfajta vegyületek
GB201107325D0 (en) Novel compounds
GB201106814D0 (en) New compounds
EP2717694A4 (en) NEW COMPOUNDS
EP2771012A4 (en) NEW CONNECTIONS
HK1191946A1 (zh) 新型六氫吡咯並咪唑酮化合物
GB201119590D0 (en) New compounds I
GB201119591D0 (en) New compounds II
GB201113971D0 (en) New compounds ii
GB201111409D0 (en) Novel compounds
GB201111410D0 (en) Novel compounds
GB201111416D0 (en) Novel compounds
GB201111476D0 (en) Novel compounds
GB201111308D0 (en) Novel compounds
GB201111229D0 (en) Novel compounds
GB201109514D0 (en) Novel compounds
GB201109508D0 (en) Novel compounds
GB201106801D0 (en) Novel compounds